Clearside Biomedical has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $15 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Clearside Biomedical is raising $15,000,000.00 in new funding. About Clearside Biomedical: Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
To learn more about Clearside Biomedical, visit http://clearsidebio.com/
Contact:
George Lasezkay, President and Chief Executive Officer
678-270-3631
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.